Empirical antibiotic therapy in intra-abdomial infections: Cases and evidence-based therapeutic recommendations;Kalkulierte Antibiotikatherapie bei intraabdominellen Infektionen - Fallbeispiele und evidenzbasierte Therapieempfehlungen

Zeitschrift fur Gastroenterologie

Volumn 51, Issue 9, 2013, Pages 1069-1081

  Stallmach, A ^a,b   Hagel, S ^a,b   Bruns, T ^a,b   Pletz, M ^a,b   Eckmann, C ^c  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Klinik für Allgemeine Viszeral   (Germany)

Author keywords

abscess; Crohn's disease; infectious colitis; intra abdominal infections; liver cirrhosis

Indexed keywords

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; GERMANY; HUMAN; INTENSIVE CARE; MORTALITY; PATHOGENESIS; PROGNOSIS; SEPTIC SHOCK;

ABDOMEN; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; EVIDENCE-BASED MEDICINE; GERMANY; INFECTIOUS DISEASE MEDICINE; PRACTICE GUIDELINES AS TOPIC;

EID: 84884148799     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0033-1335043     Document Type: Article

References (80)

1. Bodmann K. F., Grabein B., Paul-Ehrlich-Gesellschaft Ed. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J: 2010; 19 177 258
2. Brunkhorst F. M. Epidemiology, economy and practice - results of the German study on prevalence by the competence network sepsis (SepNet). Anasthesiol Intensivmed Notfallmed Schmerzther: 2006; 41 43 44 (Pubitemid 43189493)
3. Solomkin J. S., Mazuski J. E., Bradley J. S. et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis: 2010; 50 133 164
4. Eckmann C., Dryden M., Montravers P. et al. Antimicrobial treatment of "complicatedo" intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res: 2011; 16 115 126
5. DiPiro J. T., Rogers D. A. Intra-abdominal infections. In: DiPiro J. T., Talbert R. L., Yee G. C. et al. (eds) Pharmacotherapy: a pathophysiological apporach. Stanford Appleton and Lange: 1997; 2148
6. Maier S., Traeger T., Westerholt A. et al. Special aspects of abdominal sepsis. Chirurg: 2005; 76 829 836 (Pubitemid 41329961)
7. Boucher H. W., Talbot G. H., Bradley J. S. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis: 2009; 48 1 12
8. Gatermann S., Chaberny I. F., Pletz M. et al. Multiresistente pulmonale Erreger auf der Intensivstation. Der Pneumologe: 2010; 7 412 422
9. Rodriguez-Bano J., Picon E., Navarro M. D. et al. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect: 2012; 18 894 900
10. Eckmann C., Shekarriz H. Antimicrobial management of complicated intra-abdominal infections caused by resistant bacteria. Eur Infect Dis: 2012; 6 22 27
11. Paterson D. L. "Collateral damageo" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis: 2004; 38 04 S341 S345 (Pubitemid 38669889)
12. Naas T., Nordmann P., Vedel G. et al. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother: 2005; 49 4423 4424 (Pubitemid 41401006)
13. Kaase M. Bericht des NRZ für gramnegative Krankenhauserreger. Carbapenemase-tragende gramnegative Erreger im Zeitraum Mai bis Juni 2010. Epidemiologisches Bulletin: 2010; 28 267
14. Yahav D., Lador A., Paul M. et al. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother: 2011; 66 1963 1971
15. Freire A. T., Melnyk V., Kim M. J. et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis: 2010; 68 140 151
16. Tasina E., Haidich A. B., Kokkali S. et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis: 2011; 11 834 844
17. Welte T., Pletz M. W. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents: 2010; 36 391 400
18. Morrell M., Fraser V. J., Kollef M. H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother: 2005; 49 3640 3645 (Pubitemid 41233011)
19. Ruhnke M., Rickerts V., Cornely O. A. et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses: 2011; 54 279 310
20. Cornely O. A., Bassetti M., Calandra T. European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect: 2012; 18 19 37
21. Bodmann K. F. Komplizierte intraabdominelle Infektionen: Erreger, Resistenzen. Chirurg: 2010; 81 38 49
22. Gerbes A. L., Gulberg V., Sauerbruch T. et al. German S 3-guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndromeo" Z Gastroenterol: 2011; 49 749 779
23. Ginès P., Angeli P., Lenz K. et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol: 2010; 53 397 417
24. Navasa M., Follo A., Llovet J. M. et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology: 1996; 111 1011 1017 (Pubitemid 26327604)
25. Angeli P., Guarda S., Fasolato S. et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther: 2006; 23 75 84 (Pubitemid 43381169)
26. Cheong H. S., Kang C. I., Lee J. A. et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis: 2009; 48 1230 1236
27. Umgelter A., Reindl W., Miedaner M. et al. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection: 2009; 37 2 8
28. Fernandez J., Acevedo J., Castro M. et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology: 2012; 55 1551 1561
29. Ariza X., Castellote J., Lora-Tamayo J. et al. Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis. J Hepatol: 2012; 56 825 832
30. Reuken P. A., Pletz M. W., Baier M. et al. Emergence of spontaneous bacterial peritonitis due to enterococci - risk factors and outcome in a 12-year retrospective study. Aliment Pharmacol Ther: 2012; 35 1199 1208
31. Fernandez J., Navasa M., Gomez J. et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology: 2002; 35 140 148 (Pubitemid 34032554)
32. Chavez-Tapia N. C., Barrientos-Gutierrez T., Tellez-Avila F. et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. Aliment Pharmacol Ther 34 509 518
33. Fernandez J., Navasa M., Planas R. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology: 2007; 133 818 824 (Pubitemid 47374144)
34. Bruns T., Stallmach A. Spontaneous and Secondary Bacterial Peritonitis in Cirrhotic Patients with Ascites. Zentralbl Chir 2011 DOI: 10.1055/s-0031- 1283815
35. Appenrodt B., Grunhage F., Gentemann M. G. et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology: 2010; 51 1327 1333
36. Bruns T., Peter J., Reuken P. A. et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int: 2012; 32 223 230
37. Bruns T., Reuken P. A., Fischer J. et al. Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. J Hepatol: 2012; 56 1207 1208; author reply 1208-1209
38. Nischalke H. D., Berger C., Aldenhoff K. et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 55 1010 1016
39. Paul M., Silbiger I., Grozinsky S. et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006: CD003344
40. Kujath P., Rodloff A. C. Peritonitis. 2. Aufl Heidelberg Uni-med Verlag: 2005
41. Weigelt J. A. Empiric treatment options in the management of complicated intra-abdominal infections. Cleve Clin J Med: 2007; 74 04 S29 S37
42. Bassetti M., Nicolini L., Repetto E. et al. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis: 2010; 10 287
43. Eckmann C., Heizmann W. R., Leitner E. et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice. Chemotherapy: 2010; 57 275 284
44. Takesue Y., Nakajima K., Ichiki K. et al. Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant Gram-negative bacteria. J Hosp Infect: 2010; 75 28 32
45. Kollef M. H. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis: 2006; 43 02 S82 S88 (Pubitemid 44267145)
46. Sarraf-Yazdi S., Sharpe M., Bennett K. M. et al. A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit. The Journal of surgical research: 2012; 176 e73 e78
47. Steinberg D. M., Cooke W. T., Alexander-Williams J. Free perforation in Crohn's disease. Gut: 1973; 14 187 190
48. Nagler S. M., Poticha S. M. Intraabdominal abscess in regional enteritis. Am J Surg: 1979; 137 350 354 (Pubitemid 9143221)
49. Keighley M. R., Eastwood D., Ambrose N. S. et al. Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. Gastroenterology: 1982; 83 1271 1275 (Pubitemid 13235929)
50. Gervais D. A., Hahn P. F., O'Neill M. J. et al. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology: 2002; 222 645 651 (Pubitemid 34215208)
51. Lee H., Kim Y. H., Kim J. H. et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. Dig Liver Dis: 2006; 38 659 664 (Pubitemid 44356257)
52. Garcia J. C., Persky S. E., Bonis P. A. et al. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol: 2001; 32 409 412 (Pubitemid 32378273)
53. Kim H., Park D., Sohn C. I. Comparison of clinical outcomes between the patients with biliary tract infection caused by extend-spectrum beta-lactamase producing and non-producing Klebsielle pneumoniae and Escherichia coli (abstract). Gastroenterology: 2011; 140 S-393 S-394
54. Neubrand M., Sackmann M., Caspary W. F. et al. Guidelines by the German Society of Digestive and Metabolic Diseases for treatment of gallstones. German Society of Digestive and Metabolic Diseases. Z Gastroenterol: 2000; 38 449 468 (Pubitemid 30451470)
55. Attili A. F., De Santis A., Capri R. et al. The natural history of gallstones: the GREPCO experience. The GREPCO Group. Hepatology: 1995; 21 655 660
56. Wada K., Takada T., Kawarada Y. et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg: 2007; 14 52 58 (Pubitemid 46189142)
57. Miura F., Takada T., Kawarada Y. et al. Flowcharts for the diagnosis and treatment of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg: 2007; 14 27 34 (Pubitemid 46189139)
58. Sharma B. C., Agarwal D. K., Baijal S. S. et al. Endoscopic management of acute calculous cholangitis. J Gastroenterol Hepatol: 1997; 12 874 876 (Pubitemid 28088075)
59. Leung J. W., Ling T. K., Chan R. C. et al. Antibiotics, biliary sepsis, and bile duct stones. Gastrointest Endosc: 1994; 40 716 721 (Pubitemid 24366586)
60. Kaya M., Bestas R., Bacalan F. et al. Microbial profile and antibiotic sensitivity pattern in bile cultures from endoscopic retrograde cholangiography patients. World J Gastroenterol: 2012; 18 3585 3589
61. Silen W., Wertheimer M., Kirshenbaum G. Bacterial contamination of the biliary tree after choledochostomy. American journal of surgery: 1978; 135 325 327 (Pubitemid 8298444)
62. Lee C. C., Chang I. J., Lai Y. C. et al. Epidemiology and prognostic determinants of patients with bacteremic cholecystitis or cholangitis. Am J Gastroenterol: 2007; 102 563 569
63. Negm A. A., Schott A., Vonberg R. P. et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc: 2010; 72 284 291
64. Karpel E., Madej A., Buldak L. et al. Bile bacterial flora and its in vitro resistance pattern in patients with acute cholangitis resulting from choledocholithiasis. Scand J Gastroenterol: 2011; 46 925 930
65. Lode H. Microbiological and clinical aspects of aspiration pneumonia. J Antimicrob Chemother: 1988; 21 Suppl C 83 90
66. Lenz P., Conrad B., Kucharzik T. et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study. Gastrointest Endosc: 2009; 70 480 487
67. van Lent A. U., Bartelsman J. F., Tytgat G. N. et al. Duration of antibiotic therapy for cholangitis after successful endoscopic drainage of the biliary tract. Gastrointest Endosc: 2002; 55 518 522 (Pubitemid 41123503)
68. Stallmach A., Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis: 2002; 8 213 218 (Pubitemid 34546049)
69. Khanna S., Pardi D. S. IBD: Poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol: 2012; 9 307 308
70. Bauer M. P., Kuijper E. J., van Dissel J. T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect: 2009; 15 1067 1079
71. Binion D. G. Strategies for management of Clostridium difficile infection in immunosuppressed patients. Gastroenterol Hepatol: 2011; 7 750 752
72. Gerding D. N., Muto C. A., Owens R. C. Jr. Treatment of Clostridium difficile infection. Clin Infect Dis: 2008; 46 01 S32 S42 (Pubitemid 351323663)
73. Ben-Horin S., Margalit M., Bossuyt P. et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol: 2009; 7 981 987
74. Ingle M., Deshmukh A., Desai D. et al. Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis. Indian J Gastroenterol 2011 30 89 93
75. Collini P. J., Bauer M., Kuijper E. et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect: 2012; 64 131 147
76. Bossuyt P., Verhaegen J., Van Assche G. et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis: 2009; 3 4 7
77. van Nood E., Vrieze A., Nieuwdorp M. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med: 2013; 368 407 415
78. Mattila E., Arkkila P., Mattila P. S. et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Alimentary pharmacology & therapeutics: 2013; 37 122 128
79. Lancaster J. W., Matthews S. J. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther: 2012; 34 1 13
80. Blot S., De Waele J. J., Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs: 2012; 72 e17 e32